The significance of Ubiquitin proteasome pathway in cancer development

Recent Patents on Anti-Cancer Drug Discovery

Volumn 8, Issue 3, 2013, Pages 298-309

  Yerlikaya, Azmi ^a   Yöntem, Mustafa ^a  

^a DUMLUPINAR UNIVERSITY   (Turkey)

Author keywords

Apoptosis; Bortezomib; Cancer; Inhibitor; Proteasome; Proteolysis; Ubiquitin

Indexed keywords

20S PROTEASOME; 26S PROTEASOME; ALPHA FETOPROTEIN; BENZODIAZEPINE; BORTEZOMIB; CARFILZOMIB; DECARBOXYPROTHROMBIN; DEXAMETHASONE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FAS LIGAND; IMIDAZOLINE; LACTACYSTIN; NELFINAVIR; ONCOPROTEIN; ORNITHINE DECARBOXYLASE; PROTEASOME INHIBITOR; PROTEIN P53; RING FINGER PROTEIN; RITUXIMAB; SALUBRINAL; TELOMERIC REPEAT BINDING FACTOR 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN CONJUGATING ENZYME; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR;

ADENOID CYSTIC CARCINOMA; CANCER GROWTH; CANCER THERAPY; CELL CYCLE; CELL DEATH; CELL PROLIFERATION; CHRONIC LIVER DISEASE; DNA REPAIR; ENDOCYTOSIS; ENZYME ACTIVITY; HUMAN; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MANTLE CELL LYMPHOMA; MULTICENTER STUDY (TOPIC); MULTIPLE MYELOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN STRUCTURE; REVIEW; UBIQUITINATION;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PATENTS AS TOPIC; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; SIGNAL TRANSDUCTION; UBIQUITIN; UBIQUITINATION;

EID: 84888033288     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/1574891X113089990033     Document Type: Review

References (88)

1. Adams J. Development of the proteasome inhibitor PS-341. Oncologist 2002; 7(1): 9-16.
2. Rock KL, Goldberg AL. Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu Rev of Immunol 1999; 17: 739-79.
3. Ciechanover A, Heller H, Elias S, Haas AL, Hershko A. ATPdependent conjugation of reticulocyte proteins with the polypeptide required for protein degradation. Proc Natl Acad Sci USA 1980; 77(3): 1365-8.
4. Haglund K, Dikic I. Ubiquitylation and cell signaling. Embo J 2005; 24(19): 3353-9.
5. Deshaies RJ. Make it or break it-the role of ubiquitin-dependent proteolysis in cellular-regulation. Trends Cell Biol 1995; 5(11): 428-34.
6. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998; 67: 425-79.
7. Mimnaugh EG, Chen HY, Davie JR, Celis JE, Neckers L. Rapid deubiquitination of nucleosomal histones in human tumor cells caused by proteasome inhibitors and stress response inducers: Effects on replication, transcription, translation, and the cellular stress response. Biochemistry 1997; 36(47): 14418-29.
8. Seufert W, Futcher B, Jentsch S. Role of a ubiquitin-conjugating enzyme in degradation of s-phase and m-phase cycli{dotless}ns. Nature 1995; 373(6509): 78-81.
9. Yerlikaya A, Kimball SR, Stanley BA. Phosphorylation of eIF2 alpha in response to 26S proteasome inhibition is mediated by the haem-regulated inhibitor (HRI) kinase. Biochem J 2008; 412: 579-88.
10. Yerlikaya A, Stanley BA. S-adenosylmethionine decarboxylase degradation by the 26 S proteasome is accelerated by substratemediated transamination. J Biol Chem 2004; 279(13): 12469-78.
11. Mani A, Gelmann EP. The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol 2005; 23(21): 4776-89.
12. Nandi D, Tahiliani P, Kumar A, Chandu D. The ubiquitinproteasome system. J Biosci 2006; 31(1): 137-55.
13. Weissman AM. Regulating protein degradation by ubiquitination. Immunol Today 1997; 18(4): 189-98.
14. Chau V, Tobias JW, Bachmair A, Marriott D, Ecker DJ, Gonda DK, et al. A multiubiquitin chain is confined to specific lysine in a targeted short-lived protein. Science 1989; 243(4898): 1576-83.
15. Crawford LJ, Walker B, Irvine AE. Proteasome inhibitors in cancer therapy. J Cell Commun Signal 2011; 5(2): 101-10.
16. Cook JC, Chock PB. Isoforms of mammalian ubiquitin-activating enzyme. J Biol Chem 1992; 267(34): 24315-21.
17. Pelzer C, Kassner I, Matentzoglu K, Singh RK, Wollscheid HP, Scheffner M, et al. UBE1L2, a novel E1 enzyme specific for ubiquitin. J Biol Chem 2007; 282(32): 23010-4.
18. Pickart CM, Eddins MJ. Ubiquitin: Structures, functions, mechanisms. Biochim Biophys Acta-Mol Cell Res 2004; 1695(1-3): 55-72.
19. Fuchs SY, Adler V, Buschmann T, Wu X, Ronai Z. Mdm2 association with p53 targets its ubiquitination. Oncogene 1998; 17(19): 2543-7.
20. Coffino P. Antizyme, a mediator of ubiquitin-independent proteasomal degradation. Biochimie 2001; 83(3-4): 319-23.
21. Adams J. The proteasome: A suitable antineoplastic target. Nat Rev Cancer 2004; 4(5): 349-60.
22. Richardson PG, Mitsiades C, Hideshima T, Anderson KC. Proteasome inhibition in the treatment of cancer. Cell Cycle 2005; 4(2): 290-6.
23. Zwickl P, Voges D, Baumeister W. The proteasome: A macromolecular assembly designed for controlled proteolysis. Philos Trans R Soc Lond Ser B-Biol Sci 1999; 354(1389): 1501-11.
24. Kisselev AF, van der Linden WA, Overkleeft HS. Proteasome inhibitors: An expanding army attacking a unique target. Chem Biol 2012; 19(1): 99-115.
25. Mattern MR, Wu J, Nicholson B. Ubiquitin-based anticancer therapy: Carpet bombing with proteasome inhibitors vs surgical strikes with E1, E2, E3, or DUB inhibitors. Biochim Biophys Acta 2012; doi: 10. 1016/j. bbamcr. 2012. 05. 005.
26. Burger AM, Seth AK. The ubiquitin-mediated protein degradation pathway in cancer: Therapeutic implications. Eur J Cancer 2004; 40(15): 2217-29.
27. Kisselev AF, Goldberg AL. Proteasome inhibitors: From research tools to drug candidates. Chem Biol 2001; 8(8): 739-58.
28. Hoeller D, Dikic I. Targeting the ubiquitin system in cancer therapy. Nature 2009; 458(7237): 438-44.
29. Chen L, Madura K. Increased proteasome activity, ubiquitinconjugating enzymes, and eEF1A translation factor detected in breast cancer tissue. Cancer Res 2005; 65(13): 5599-606.
30. Albitar, M., Ma, W., Zhang, K., Zhang, X., Wang, X., Qu, K., Sferruzza, A. Ubiquitin proteasome system profiling and the use thereof in clinical application for cancer diagnosis. US20110053197 (2011).
31. McCawley N, Conlon S, Hector S, Cummins RJ, Dicker P, Johnston PG, et al. Analyzing proteasomal subunit expression reveals Rpt4 as a prognostic marker in stage II colorectal cancer. Int J Cancer 2012; 131(4): E494-E500.
32. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100(1): 57-70.
33. Lipkowitz S. The role of the ubiquitination-proteasome pathway in breast cancer: Ubiquitin mediated degradation of growth factor receptors in the pathogenesis and treatment of cancer. Breast Cancer Res 2003; 5(1): 8-15.
34. Bisson SA, Ujack EE, Robbins SM. Isolation and characterization of a novel, transforming allele of the c-Cbl proto-oncogene from a murine macrophage cell line. Oncogene 2002; 21(23): 3677-87.
35. Calin G, Herlea V, Barbanti-Brodano G, Negrini M. The coding region of the Bloom syndrome BLM gene and of the CBL protooncogene is mutated in genetically unstable sporadic gastrointestinal tumors. Cancer Res 1998; 58(17): 3777-81.
36. Longva KE, Blystad FD, Stang E, Larsen AM, Johannessen LE, Madshus IH. Ubiquitination and proteasomal activity is required for transport of the EGF receptor to inner membranes of multivesicular bodies. J Cell Biol 2002; 156(5): 843-54.
37. Piperdi, B. Combined treatment with bortezomib and an epidermal growth factor receptor kinase inhibitor. US20060084691 (2006).
38. Petak I, Houghton JA, Kopper L. Molecular targeting of cell death signal transduction pathways in cancer. Curr Signal Transduct Ther 2006; 1(1): 113-31.
39. Kalejta RF, Shenk T. Proteasome-dependent, ubiquitin-independent degradation of the Rb family of tumor suppressors by the human cytomegalovirus pp71 protein. Proc Natl Acad Sci USA 2003; 100(6): 3263-8.
40. Grana X, Garriga J, Mayol X. Role of the retinoblastoma protein family, pRB, p107 and p130 in the negative control of cell growth. Oncogene 1998; 17(25): 3365-83.
41. Hoekstra, M. F., Xie, W., Murray, B. W., Mercurio, F. M. Methods for modulating signal transduction mediated by TGF-and related proteins. US7358056 (2008).
42. Fukasawa H, Yamamoto T, Fujigaki Y, Misaki T, Ohashi N, Takayama T, et al. Reduction of transforming growth factor-beta type II receptor is caused by the enhanced ubiquitin-dependent degradation in human renal cell carcinoma. Int J Cancer 2010; 127(7): 1517-25.
43. Wang, T. Composition and methods for modulating TGF-beta signaling. US20020076799 (2002).
44. Bryan TM, Cech TR. Telomerase and the maintenance of chromosome ends. Curr Opin Cell Biol 1999; 11(3): 318-24.
45. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, et al. Extension of life-span by introduction of telomerase into normal human cells. Science 1998; 279(5349): 349-52.
46. Chang W, Dynek JN, Smith S. TRF1 is degraded by ubiquitinmediated proteolysis after release from telomeres. Genes Dev 2003; 17(11): 1328-33.
47. Lee TH, Perrem K, Harper JW, Lu KP, Zhou XZ. The F-box protein FBX4 targets PIN2/TRF1 for ubiquitin-mediated degradation and regulates telomere maintenance. J Biol Chem 2006; 281(2): 759-68.
48. Lahav-Baratz S, Ben-Izhak O, Sabo E, Ben-Eliezer S, Lavie O, Ishai D, et al. Decreased level of the cell cycle regulator p27 and increased level of its ubiquitin ligase Skp2 in endometrial carcinoma but not in normal secretory or in hyperstimulated endometrium. Mol Hum Reprod 2004; 10(8): 567-72.
49. Chiarle R, Budel LM, Skolnik J, Frizzera G, Chilosi M, Corato A, et al. Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood 2000; 95(2): 619-26.
50. Meissner M, Reichenbach G, Stein M, Hrgovic I, Kaufmann R, Gille J. Down-regulation of vascular endothelial growth factor receptor 2 is a major molecular determinant of proteasome inhibitor-mediated antiangiogenic action in endothelial cells. Cancer Res 2009; 69(5): 1976-84.
51. Rahimi N. The ubiquitin-proteasome system meets angiogenesis. Mol Cancer Ther 2012; 11(3): 538-48.
52. Sunwoo JB, Chen Z, Dong G, Yeh N, Bancroft CG, Sausville E, et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001; 7(5): 1419-28.
53. Blank M, Shiloh Y. Programs for cell death-Apoptosis is only one way to go. Cell Cycle 2007; 6(6): 686-95.
54. Zhang HG, Wang JH, Yang XW, Hsu HC, Mountz JD. Regulation of apoptosis proteins in cancer cells by ubiquitin. Oncogene 2004; 23(11): 2009-15.
55. Christian PA, Fiandalo MV, Schwarze SR. Possible role of death receptor-mediated apoptosis by the E3 ubiquitin ligases Siah2 and POSH. Mol Cancer 2011; 10: 57.
56. Tanimoto Y, Kizaki H. Proteasome inhibitors block Ras/ERK signaling pathway resulting in the downregulation of fas ligand expression during activation-induced cell death in T cells. J Biochem 2002; 131(3): 319-26.
57. el-Deiry WS. Regulation of p53 downstream genes. Semin Cancer Biol 1998; 8(5): 345-57.
58. Haupt S, Berger M, Goldberg Z, Haupt Y. Apoptosis-the p53 network. J Cell Sci 2003; 116(20): 4077-85.
59. Maki CG, Huibregtse JM, Howley PM. In vivo ubiquitination and proteasome-mediated degradation of p53. Cancer Res 1996; 56(11): 2649-54.
60. Lopes UG, Erhardt P, Yao RJ, Cooper GM. p53-dependent induction of apoptosis by proteasome inhibitors. J Biol Chem 1997; 272(20): 12893-6.
61. MacLaren AP, Chapman RS, Wyllie AH, Watson CJ. p53-dependent apoptosis induced by proteasome inhibition in mammary epithelial cells. Cell Death Differ 2001; 8(3): 210-8.
62. Pandit B, Gartel AL. Proteasome inhibitors induce p53-independent apoptosis in human cancer cells. Am J Pathol 2011; 178(1): 355-60.
63. Yerlikaya A, Okur E, Ulukaya E. The p53-independent induction of apoptosis in breast cancer cells in response to proteasome inhibitor bortezomib. Tumor Biol 2012; 33: 1385-92.
64. Yang YL, Kitagaki J, Dai RM, Tsai YC, Lorick KL, Ludwig RL, et al. Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics. Cancer Res 2007; 67(19): 9472-81.
65. Ceccarelli DF, Tang XJ, Pelletier B, Orlicky S, Xie WL, Plantevin V, et al. An allosteric inhibitor of the human Cdc34 ubiquitinconjugating enzyme. Cell 2011; 145(7): 1075-87.
66. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. In vivo activation of the p53 pathway by small-molecule antagonists of Mdm2. Science 2004; 303(5659): 844-8.
67. Shangary S, Wang SM. Targeting the Mdm2-p53 interaction for cancer therapy. Clin Cancer Res 2008; 14(17): 5318-24.
68. Saha MN, Jiang HA, Chang H. Molecular mechanisms of nutlininduced apoptosis in multiple myeloma evidence for p53-transcription-dependent and-independent pathways. Cancer Biol Ther 2010; 10(6): 567-78.
69. Brown CJ, Cheok CF, Verma CS, Lane DP. Reactivation of p53: From peptides to small molecules. Trends Pharmacol Sci 2011; 32(1): 53-62.
70. Colland F, Formstecher E, Jacq X, Reverdy C, Planquette C, Conrath S, et al. Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells. Mol Cancer Ther 2009; 8(8): 2286-95.
71. de Bettignies G, Coux O. Proteasome inhibitors: Dozens of molecules and still counting. Biochimie 2010; 92(11): 1530-45.
72. Frankland-Searby S, Bhaumik SR. The 26S proteasome complex: An attractive target for cancer therapy. Biochim Biophys Acta-Rev Cancer 2012; 1825(1): 64-76.
73. Orlowski RZ, Kuhn DJ. Proteasome inhibitors in cancer therapy: Lessons from the first decade. Clin Cancer Res 2008; 14(6): 1649-57.
74. Wunderlich A, Arndt T, Fischer M, Roth S, Ramaswamy A, Greene BH, et al. Targeting the proteasome as a promising therapeutic strategy in thyroid cancer. J Surg Oncol 2012; 105(4): 357-64.
75. Stinchcombe TE, Mitchell BS, Depcik-Smith N, Adams J, Elliott P, Shea TC, et al. PS-341 is active in multiple myeloma: Preliminary report of a phase I trial of the proteasome inhibitor PS-341 in patients with hematologic malignancies. Blood 2000; 96(11): 516A.
76. Yerlikaya A, Erin N. Differential sensitivity of breast cancer and melanoma cells to proteasome inhibitor Velcade. Int J Mol Med 2008; 22(6): 817-23.
77. Yerlikaya A, Okur E, Aeker S, Erin N. Combined effects of the proteasome inhibitor bortezomib and Hsp70 inhibitors on the B16F10 melanoma cell line. Mol Med Report 2010; 3(2): 333-9.
78. Ramalingam SS, Davies AM, Longmate J, Edelman MJ, Lara PN, Jr., Vokes EE, et al. Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: A California Cancer Consortium Phase II study (NCI 7003). J Thorac Oncol 2011; 6(10): 1741-5.
79. Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006; 24(30): 4867-74.
80. Argiris A, Ghebremichael M, Burtness B, Axelrod RS, Deconti RC, Forastiere AA. A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: A Trial of the Eastern Cooperative Oncology Group (E1303). Cancer 2011; 117(15): 3374-82.
81. Lamm W, Kaufmann H, Raderer M, Hoffmann M, Chott A, Zielinski C, Drach J. Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma. Haematol-Hematol J 2011; 96(7): 1008-14.
82. Kawabata S, Gills JJ, Mercado-Matos JR, LoPiccolo J, Wilson W, Hollander MC, et al. Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells. Cell Death Dis 2012; doi: 10. 1038/cddis. 2012. 87.
83. Brewer JW, Diehl JA. PERK mediates cell-cycle exit during the mammalian unfolded protein response. Proc Natl Acad Sci USA 2000; 97(23): 12625-630.
84. Schewe, D. M., Aguirre-Ghiso, J. A. Method of treating cancer with a combination of a proteasome inhibitor and salubrinal. US20120142634 (2012).
85. Li, R., Cui, J., Zhu, Y., Yao, S., Ge, Z., Cheng, T. Tripeptide boronic acid or boronic ester, preparative method and use thereof. US20120135921 (2012).
86. Piva R, Ruggeri B, Williams M, Costa G, Tamagno I, Ferrero D, et al. CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood 2008; 111(5): 2765-75.
87. Ling, S. C. W., Allen, J. D. Assay for response to proteasome inhibitors. US20080227096 (2008).
88. Vasilescu J, Smith JC, Ethier M, Figeys D. Proteomic analysis of ubiquitinated proteins from human MCF-7 breast cancer cells by immunoaffinity purification and mass spectrometry. J Proteome Res 2005; 4(6): 2192-200.